Spondyloarthritis & psoriatic arthritis
Effect of Bimekizumab on Patient-Reported Outcomes and Work Productivity in Patients With Psoriatic Arthritis: 1-Year Results From 2 Phase III Studies
Authors' conclusion
Bimekizumab treatment resulted in sustained improvements in patient-reported symptoms, HRQOL, and work productivity up to 1 year in bDMARD-naïve and TNFi-IR patients with active PsA.
Study context
- Population
- Patients with active PsA, biologic disease-modifying antirheumatic drug (bDMARD)-naïve or TNFi-IR
- Comparison
- Bimekizumab 160 mg SC every 4 weeks vs placebo
- Primary endpoint
- Patient-reported pain, fatigue, physical function, HRQOL and work productivity
- Follow-up
- Week 52/40
Methodological detailsdouble-blind, placebo-controlled to 16 weeks, open-label extension (BE VITAL)
- Double-blind
- Placebo-controlled to 16 weeks
- Open-label extension (BE VITAL)
Primary result
As reported in the abstract
Mean improvements from baseline in PROs, bimekizumab-randomized
- Pain (VAS 0-100 mm), bDMARD-naïve
- −30.5
- Pain (VAS 0-100 mm), TNFi-IR
- −31.8
- Fatigue (FACIT-Fatigue 0-52), bDMARD-naïve
- 5.3
- Fatigue (FACIT-Fatigue 0-52), TNFi-IR
- 6.0
- Physical function (HAQ-DI 0-3), bDMARD-naïve
- −0.34
- Physical function (HAQ-DI 0-3), TNFi-IR
- −0.39
- Health-related quality of life (HRQOL) (SF-36 PCS), bDMARD-naïve
- 8.1
- HRQOL (SF-36 PCS), TNFi-IR
- 8.4
Further findings
Work productivity (WPAI) · week 52
- Improvements in overall work impairment sustained among bimekizumab-randomized patients
- Similar trends for absenteeism, presenteeism and activity impairment
Original publication
Effect of Bimekizumab on Patient-Reported Outcomes and Work Productivity in Patients With Psoriatic Arthritis: 1-Year Results From 2 Phase III Studies. J Rheumatol. Published 1 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →